Recent progress of imaging agents for Parkinson's disease

Area of Science:

• Neuroscience
• Radiochemistry
• Medical Imaging

Background:

• Parkinson's disease (PD) is a progressive neurodegenerative disorder.
• Mitochondrial dysfunction, oxidative stress, and protein aggregation contribute to PD pathogenesis.
• Current imaging methods like CT and MRI have limitations in early and atypical cases.

Purpose of the Study:

• To review advancements in radionuclide imaging for Parkinson's disease.
• To highlight the potential of nuclear radiopharmaceuticals in early PD diagnosis.
• To discuss the role of coordination chemistry and chelator design in targeted radionuclide delivery.

Main Methods:

• Comprehensive literature review of radionuclide imaging techniques in PD.
• Analysis of radiopharmaceuticals targeting PD-related transporters and receptors (e.g., dopamine, serotonin).
• Evaluation of sensitivity and specificity of nuclear imaging in preclinical and atypical PD.

Main Results:

• Non-invasive nuclear radiopharmaceuticals demonstrate high sensitivity and specificity for early PD detection.
• Targeted delivery of radionuclides via PD-related molecules enhances diagnostic accuracy.
• Radionuclide imaging shows promise in differentiating PD from other neurological conditions.

Conclusions:

• Nuclear imaging represents a significant breakthrough in the early diagnosis of Parkinson's disease.
• Targeted radionuclide agents offer a sensitive and specific approach to visualize PD-related pathology.
• Further development in radiochemistry and chelator design will enhance the clinical utility of these imaging agents.